HYDERABAD: Bharat Serums and Vaccines Limited (BSV) is investing Rs 200 crore in setting up a global speciality injectables manufacturing facility in Hyderabads Genome Valley for which it broke ground on Thursday. The complex injectables facility, which will cater to the domestic as well as exports markets, is coming up on a 10-acre land parcel with the phase-1 expected to be ready for production in 2026, BSV managing director & CEO Sanjiv Navangul told TOI. The entire project will be ready in another four years and will provide about 200-300 jobs as it will be a highly automated facility, Navangul said, adding that it will manufacture womens health products, emergency products such as anti-snake venom and rabies injections, immunoglobulins, hormones and even vaccines. The facility will significantly ramp up BSVs injectables capacity with the commissioning of the fill-finish formulations line in phase-1 and an additional multi-product line in phase-2, the company said. "We will have a general line, a complex injectables line, a hormones line and some space for an additional line to produce vaccines. We need to determine what kind of vaccines can be made here," Navangul said.BSV currently has a manufacturing facility in Ambernath in Maharashtra catering to domestic as well as over 80 export markets, and an API (active pharmaceutical ingredients) manufacturing facility in Aachen, Germany, that serves the international markets.

Stay updated with all the Hyderabad Latest News headlines here. For more exclusive & live news updates from all around India, stay connected with NYOOOZ.